We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Novel Antigen Improves Detection of Anti-Borrelia Antibodies

By LabMedica International staff writers
Posted on 25 Mar 2013
A recombinant antigen has been developed which greatly increases the specificity of anti-Borrelia antibody detection in the diagnosis of Lyme disease. More...


The dimeric outer surface protein C (OspC antigen) provides over 30% higher specificity than traditionally used monomeric forms, while maintaining a high sensitivity, especially in early stage infections.

Recombinant OspC has, for the first time, has been produced in dimeric form using state-of-the-art molecular biological methods. The dimeric OspC advanced antigen demonstrates the same characteristics as the native dimeric protein. Its exceptionally high specificity minimizes the risk of false-positive results and at the same time, it retains a high sensitivity.

Scientists at EUROIMMUN (Luebeck, Germany) have successfully produced recombinant, covalently bound dimeric OspC using genetic techniques which in contrast to native protein which is difficult to isolate, recombinant OspC advanced can be produced using standardized methods, ensuring a highly consistent antigen quality. The OspC advanced antigen improves the performance of both enzyme-linked immunosorbent assays (ELISA) and immunoblots for Borrelia diagnostics.

The Anti-Borrelia Select ELISA immunoglobulin M (IgM), which contains OspC advanced and other diagnostically relevant antigens in its antigenic substrate, provides exceptionally high sensitivity and specificity in the screening step for early-stage borreliosis. The confirmatory immunoblot Anti-Borrelia EUROLINE-RN-AT-adv (IgM), which includes OspC advanced from four different human pathogenic species, Borrelia afzelii, B. burgdorferi, B. garinii, and B. spielmanii, together with the outer surface protein of B. burgdorferi, known as VlsE, and other highly specific antigens, ensures accurate and reliable results in the confirmation of infections.

Antibodies against OspC are found in up to 90% of persons infected with Borrelia and represent the most important marker for early-stage borreliosis. Over 65,400 cases of Lyme borreliosis occur in Europe each year and over 27,000 cases were reported from the USA in 2012. The Anti-Borrelia Select ELISA and the Anti-Borrelia EUROLINE-RN-AT-adv are fast and easy to perform and can be fully automated, making them ideal for use in routine diagnostics.

Related Links:

EUROIMMUN




Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Automated Staining Unit
RAL Stainer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.